AdAlta Limited (1AD.AX)
AUD 0.02
(-6.25%)
AUD 0.02
(-6.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -845.17 Thousand AUD | 18.12% |
| 2023 | -775.65 Thousand AUD | 83.35% |
| 2022 | -4.65 Million AUD | -13.49% |
| 2021 | -4.1 Million AUD | -249.22% |
| 2020 | -1.17 Million AUD | 78.85% |
| 2019 | -5.55 Million AUD | -140.93% |
| 2018 | -2.3 Million AUD | 62.95% |
| 2017 | -6.22 Million AUD | 41.88% |
| 2016 | -10.71 Million AUD | -30620.89% |
| 2015 | -34.86 Thousand AUD | 90.88% |
| 2014 | -382.3 Thousand AUD | 33.51% |
| 2013 | -575 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -1.51 Million AUD | -95.73% |
| 2024 Q2 | -1.67 Million AUD | 0.0% |
| 2024 Q4 | -845.17 Thousand AUD | 0.0% |
| 2023 Q2 | -3.32 Million AUD | 0.0% |
| 2023 FY | -775.65 Thousand AUD | 83.35% |
| 2023 Q4 | -775.65 Thousand AUD | 0.0% |
| 2022 Q2 | -6.67 Million AUD | 0.0% |
| 2022 Q4 | -4.65 Million AUD | 0.0% |
| 2022 FY | -4.65 Million AUD | -13.49% |
| 2021 Q2 | -8.06 Million AUD | 0.0% |
| 2021 Q4 | -4.1 Million AUD | 0.0% |
| 2021 FY | -4.1 Million AUD | -249.22% |
| 2020 Q2 | -4.05 Million AUD | 0.0% |
| 2020 FY | -1.17 Million AUD | 78.85% |
| 2020 Q4 | -1.17 Million AUD | 0.0% |
| 2019 FY | -5.55 Million AUD | -140.93% |
| 2019 Q2 | -5.35 Million AUD | 0.0% |
| 2019 Q4 | -5.55 Million AUD | 0.0% |
| 2018 Q4 | -2.3 Million AUD | 0.0% |
| 2018 FY | -2.3 Million AUD | 62.95% |
| 2018 Q2 | -5.26 Million AUD | 0.0% |
| 2017 FY | -6.22 Million AUD | 41.88% |
| 2017 Q4 | -6.22 Million AUD | 0.0% |
| 2017 Q2 | -8.77 Million AUD | 0.0% |
| 2016 Q3 | -485.55 Thousand AUD | 0.0% |
| 2016 FY | -10.71 Million AUD | -30620.89% |
| 2016 Q1 | - AUD | 0.0% |
| 2016 Q4 | -485.55 Thousand AUD | 0.0% |
| 2015 FY | -34.86 Thousand AUD | 90.88% |
| 2014 FY | -382.3 Thousand AUD | 33.51% |
| 2013 FY | -575 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 95.528% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 13.943% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 116.679% |
| Biome Australia Limited | -1.56 Million AUD | 45.92% |
| Patrys Limited | -2.24 Million AUD | 62.28% |
| Orthocell Limited | -19.92 Million AUD | 95.758% |
| Imugene Limited | -91.56 Million AUD | 99.077% |
| Noxopharm Limited | -2.31 Million AUD | 63.569% |
| PYC Therapeutics Limited | -65.76 Million AUD | 98.715% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 72.317% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 91.684% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 86.635% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 86.38% |
| CSL Limited | 15.76 Billion AUD | 100.005% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 93.353% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -19.113% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 99.538% |
| Starpharma Holdings Limited | -19.83 Million AUD | 95.738% |
| Nanollose Limited | -96.22 Thousand AUD | -778.33% |
| Memphasys Limited | 4.13 Million AUD | 120.438% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 85.972% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 82.94% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 53.653% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 98.934% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 31.753% |
| Race Oncology Limited | -17.18 Million AUD | 95.083% |
| Nyrada Inc. | -4.76 Million AUD | 82.279% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 99.201% |
| Dimerix Limited | -21.99 Million AUD | 96.157% |
| PharmAust Limited | -9.71 Million AUD | 91.3% |
| Immutep Limited | -122.18 Million AUD | 99.308% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 99.381% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 93.228% |
| BTC Health Limited | -2.02 Million AUD | 58.204% |
| Acrux Limited | -1.45 Million AUD | 42.032% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 95.056% |
| Biotron Limited | -386.06 Thousand AUD | -118.918% |
| Tissue Repair Ltd | -16.44 Million AUD | 94.859% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 95.45% |
| Hexima Limited | -2.22 Million AUD | 62.035% |
| AnteoTech Limited | -5 Million AUD | 83.102% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 95.193% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 75.114% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 84.141% |
| Actinogen Medical Limited | -9.13 Million AUD | 90.745% |
| Immuron Limited | -11.48 Million AUD | 92.64% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 94.689% |